Table 6.
List of ongoing clinical trials including combination of new multitarget agents and FLT3i or hypomethylating agents.
| ClinicalTrial Id. | Drug/Drugs Combination | Phase | Setting |
|---|---|---|---|
| NCT05023707 | anti-FLT3 CAR-T | I–II | RR FLT3+ AML |
| NCT04518345 | Dubermatinib | I–II | RR FLT3+ AML |
| NCT05241106 | HYML-122 | II | RR FLT3+ AML |
| NCT05010122 | ASTX727, Venetoclax, and Gilteritinib | I–II | FLT3+ RR/DE NOVO AML; HR-MDS |
| NCT04669067 | TL-895, KRT-232 | I–II | RR TP53wt AML |
| NCT05028751 | Lanraplenib and Gilteritinib | I–II | RR FLT3+ AML |
| NCT04716114 | SKLB1028 vs. salvage | III | RR FLT3+ AML |
| NCT04842370 | PHI-101 | I | FLT3+/− AML |
| NCT05143996 | CLN-049 | I | RR FLT3+/− AML |
| NCT03922100 | NMS-03592088 | II | RR FLT3+ AML; CMML |
| NCT04827069 | Clifutinib Besylate | I | RR FLT3+ AML |
| NCT03412292 | MAX-40279 | I | RR FLT3+ AML |
| NCT04278768 | CA-4948 +/-Azacitidine+Venetoclax | I–II | RR FLT3+/− AML |
| NCT05061147 | MAX-40279-01 | I–II | RR AML |
| NCT05279859 | ERAS-007/ERAS-601+ Gilteritinib | I–II | RR FLT3+ AML |
| NCT03513484 | Nintedanib | I | RR AML |
| NCT04477291 | CG-806 | I | FLT3+/− RR AML |